Employees: 73
Size Assembly Biosciences (ASMB) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $458M, the 2740th largest of 3,085 United States companies the cockpit tracks. Shares closed at $22.39 on 18 Nov 2026.
Performance Over six months the shares fell 14.7%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 80.2% over the last twelve months (peer median +11.5%); the operating margin is -31.8% (peer median 6.0%).
Valuation It trades at 2.2× enterprise value to sales against a peer median of 4.9× (5th cheapest of 19).
Short interest Short interest is 14.9% of the free float (30 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $67.0M | $72.3M | $28.5M | $7.16M | $0 |
| Revenue growth | — | +154% | +298% | — | — |
| Gross profit | $66.9M | $72.2M | $28.4M | $6.71M | -$498,000 |
| EBITDA | -$21.2M | -$12.0M | -$45.3M | -$64.2M | -$92.5M |
| Net income | -$11.1M | -$6.12M | -$40.2M | -$61.2M | -$93.1M |
| Free cash flow | -$40.7M | -$41.2M | -$51.1M | $22.5M | -$84.6M |
| Capital expenditure | $164,000 | $66,000 | $28,000 | $255,000 | $102,000 |
| Total debt | $2.21M | $2.63M | $3.09M | $2.34M | $3.46M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASMB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.7% | -4.2% | 6th highest of 21 |
| 6-month return | -14.7% | -0.4% | 8th lowest of 20 |
| Distance from 52-week high | -43.6% | -32.1% | 8th lowest of 21 |
| Revenue growth (TTM) | +80.2% | +11.5% | highest of 20 |
| Operating margin | -31.8% | 6.0% | 5th lowest of 19 |
| EV / Sales | 2.2× | 4.9× | 5th cheapest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | 2.2× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | 10.8× | 44.1% | +1.0% |
| Gufic Biosciences GUFICBIO.NS | India | $452M | +48% | +17% | 14% | 4.3× | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $449M | -21% | -9% | 5% | 2.4× | 4.5% | +3.3% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Dong-A Socio 000640.KS | South Korea | $447M | -8% | +11% | 7% | 0.7× | -6.6% | +12.8% |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |
| Zhejiang Chengyi Pharmaceutical 603811.SS | China | $445M | -21% | +5% | 19% | 3.4× | 1.3% | +1.3% |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| RPG Life Sciences RPGLIFE.NS | India | $443M | +10% | +15% | 17% | 5.3× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| Cachet Pharmaceutical 002462.SZ | China | $441M | -25% | -14% | 0% | 0.2× | -9.9% | -3.4% |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |